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Abstract: Much of the current innovation in advanced materials is occurring at the nanoscale,
specifically in manufactured nanomaterials (MNs). MNs display unique attributes and behaviors,
and may be biologically and physically unique, making them valuable across a wide range of
applications. However, as the number, diversity and complexity of MNs coming to market continue
to grow, assessing their health and environmental risks with traditional animal testing approaches is
too time- and cost-intensive to be practical, and is undesirable for ethical reasons. New approaches
are needed that meet current requirements for regulatory risk assessment while reducing reliance
on animal testing and enabling safer-by-design product development strategies to be implemented.
The adverse outcome pathway (AOP) framework presents a sound model for the advancement of
MN decision making. Yet, there are currently gaps in technical and policy aspects of AOPs that
hinder the adoption and use for MN risk assessment and regulatory decision making. This review
outlines the current status and next steps for the development and use of the AOP framework in
decision making regarding the safety of MNs. Opportunities and challenges are identified concerning
the advancement and adoption of AOPs as part of an integrated approach to testing and assessing
(IATA) MNs, as are specific actions proposed to advance the development, use and acceptance of
the AOP framework and associated testing strategies for MN risk assessment and decision making.
The intention of this review is to reflect the views of a diversity of stakeholders including experts,
researchers, policymakers, regulators, risk assessors and industry representatives on the current status,
needs and requirements to facilitate the future use of AOPs in MN risk assessment. It incorporates the
views and feedback of experts that participated in two workshops hosted as part of an Organization
for Economic Cooperation and Development (OECD) Working Party on Manufactured Nanomaterials
(WPMN) project titled, “Advancing AOP Development for Nanomaterial Risk Assessment and
Categorization”, as well as input from several EU-funded nanosafety research consortia.
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Nanomaterials 2020, 10, 1229; doi:10.3390/nano10061229 www.mdpi.com/journal/nanomaterials
Nanomaterials 2020, 10, 1229 2 of 20
1. Introduction
Manufactured nanomaterials (MNs), as well as other advanced and emerging materials (e.g.,
composites incorporating MNs), offer significant benefits to consumers, including technological
innovation, improved product performance and more sustainable alternatives to current technologies [1].
However, safety evaluations of these materials are lagging due to testing challenges, the number,
diversity and complexity of MNs coming to market, and the fact that the requirements of regulatory
organizations are evolving as understanding of the technology develops. Currently, toxicological
assessments of MNs require individual assessments of health and environmental endpoints using
traditional animal testing methods, an approach that is too time- and cost-intensive to be practical,
as well as being ethically concerning. Today’s toxicity testing landscape is facing pressure to enhance
transparency and incorporate up-to-date scientific understanding in risk assessments and related
decision-making. Regulators must accurately assess the safety of tens of thousands of new and
existing chemical substances, but the resources allotted for safety assessments are often static or even
decreasing [2]. Policy is shifting globally toward the reduction and eventual elimination of animal
studies, favoring alternative methods for all chemicals (e.g., in the EU [3] and the US [4].
The science required to address the technical challenges of transitioning to alternative (nonanimal)
toxicity testing is progressing, but efforts are needed to incorporate these developments into decision
making and to guide the science to address data and methodological gaps hindering regulatory
risk assessment [5]. Understanding the mechanisms-of-action underlying adverse health effects is
an essential prerequisite for the development of alternative tests for decision-making [6]. Over the
past several decades, significant advances have been made in toxicological evaluations that utilize in
silico, in chemico, in vitro and ex vivo approaches to predict the hazards of new chemicals, including
MNs, without animal testing [2]. Improvements in computational capabilities have made in silico
modeling experiments more accurate and the ability to model complex system responses more
feasible. Advances in genomics and proteomics have improved our understanding of how changes
in gene and protein expression may indicate the biological events that lead to adverse outcomes
in organisms, and bioinformatics has led to the development of methods and tools to analyze the
enormous amounts of data generated through these approaches. In vitro models have advanced,
improving the characterization of complex biological systems. These new toxicological tools evaluate
biological responses on the molecular, subcellular, cellular and tissue levels, and offer risk assessors
more mechanistic information than ever before.
Currently, however, few in vitro and ex vivo tests are accepted for use in regulatory
decision-making, largely due to a lack of formal validation. The widely acknowledged challenges for
alternative testing approaches apply to conventional chemicals and MNs alike, but these issues are
further complicated for MNs. MN toxicity testing is challenging, in part because of their unique physical
and chemical properties. MN dose-response relationships may differ from those of conventional
materials. Dose-response relationships for conventional materials are based on dose in mass terms,
and do not account for the potentially enhanced toxicity caused by the particle aspects and increased
specific surface area of MNs. In addition, identifying groups for categorization based on the biological
effects arising from small changes in the MN physical and chemical characteristics is not easy.
MN toxicity has been shown to be influenced by several physical–chemical properties, including
dissolution rate (ion release), electronic band gap, aspect ratio, dispersibility in solution, contaminants,
particle size and surface chemistry. These physical–chemical characteristics are all interconnected,
and determining the contribution of a single parameter to toxicity remains difficult. Regulatory
agencies have recognized that more efficient testing strategies are needed for MNs, but that they also
require further development and verification before incorporation into regulatory testing guidance
documents. How to incorporate and use in vitro and ex vivo data to assess the risks of MNs and
other new chemicals often remains unclear; the translation of these approaches from experimental to
regulatory applications remains difficult.
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The dual challenge of advancing MN risk assessment while reducing costs and reliance on animal
testing presents an opportunity to develop smarter approaches to screening which prioritize novel
nanoscale materials. Doing so will require a coordinated response that adopts science into decision
making processes and bridges current knowledge gaps. The AOP framework is an evidence-based
approach that is expected to aid in the resolution of several twenty-first century challenges regarding
chemical and nano-specific safety assessments [7–9]. Significant progress has been made in AOP
development, application and use over the last decade, including methods, resources and tools to adopt
AOPs as part of an integrated approach to testing and assessment (IATA) that utilizes alternative testing
data for decision making. The AOP framework offers a systematic, mechanistic approach to assess
MN-induced risks with data from nonanimal testing, thereby both enabling the development of cost-
and time-efficient testing strategies and the implementation of safe-by-design approaches, and reducing
reliance on animal testing. Although the science behind AOPs has advanced considerably, a number
of barriers remain regarding the adoption of AOPs for risk assessments of MNs. An international,
coordinated effort is needed to address the technical and translational issues in order to realize the
potential of AOPs for evidence-based decision making.
Recognizing this potential, a number of initiatives are developing MN-relevant AOPs. Notably,
the EU and the OECD are both spearheading major initiatives, including the EU H2020 SmartNanoTox
program and related projects, as well as the OECD AOP Development Programme. The promise
of the AOP framework is confirmed in MN-specific guidance documents, such as the European
Food Safety Authority (EFSA), “Guidance on risk assessment of the application of nanoscience and
nanotechnologies in the food and feed chain [10],” which states that “The Organization for Economic
Co-operation and Development now also explores Integrated Approach to Testing and Assessment
(IATA) and promotes the use of AOPs to build risk assessment, while assessing all the existing data.”
At the same time, however, more work is needed. The EFSA guidance, for instance, goes on
to say that “The developments in efficient testing strategies and AOPs for nanomaterials are highly
acknowledged, though they need further development and verification before incorporation into
guidance documents can be considered.”
This review describes the AOP framework and its current status in greater detail, outlines
challenges facing its advancement and adoption, and recommends specific actions needed to mature
the concept and advance its use for decision making which is specific to MNs. The recommendations
are organized into short-, medium- and long-term actions.
2. Materials and Methods
This review reflects the views of a diversity of stakeholders including experts, researchers,
policymakers, regulators, risk assessors and industry representatives on the current status, needs and
requirements to facilitate future use of AOPs in MN risk assessment. It incorporates the views and
feedback of experts that participated in two workshops hosted as part of an Organization for Economic
Cooperation and Development (OECD) Working Party on Manufactured Nanomaterials (WPMN)
project titled, “Advancing AOP Development for Nanomaterial Risk Assessment and Categorization
(NanoAOP project)”. The first workshop was hosted on 19 September, 2018 during the NanoToxicology
conference in Neuss, Germany. The second workshop was held on 11 September, 2019 at the OECD
Conference Centre in Boulogne-Billancourt, France, and presented the results of three related projects
addressing the development and use of AOPs for MN risk assessment: (1) the OECD WPMN NanoAOP
project; (2) the Horizon 2020 (H2020) project SmartNanoTox; and (3) the H2020 project PATROLS.
Over 40 workshop participants from Canada, Chile, Denmark, Finland, France, Germany, Ireland,
Italy, Japan, Korea, Netherlands, Switzerland, Turkey, U.K. and the U.S. were divided into three groups,
with discussions in each centered around one of three central themes (Table 1).
Among other experts, participants weighed in on an earlier draft of this work and related
deliverables [11], in terms of the needs and priorities regarding the use of AOPs in risk assessment.
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Rapporteurs from breakout groups recorded the responses, comments and recommendations from the
experts, which were collated into a workshop summary report to be published in 2020/2021.
Table 1. Discussion themes posed to OECD workshop participants.
1. How can the use of the AOP framework be advanced for decision making about the safety of MNs?
2. What is needed for the future development of MN-relevant AOPs and supporting data?
3. How can the development and adoption of in vitro assays be targeted to KEs to enable the use of AOPs
as part of an IATA for MN decision making?
3. Overview of the AOP Framework and Current Status
3.1. Overview
AOPs clarify relationships across biological levels of organization (including molecular, subcellular,
cellular, tissue, organ, organism and whole populations), using cause-and-effect relationships to connect
molecular initiating events (MIE) to adverse outcomes (AO). AOs are negative biological consequences
resulting from chemical exposure; they are typically measured at higher levels of biological organization
and are important for regulatory decision making, e.g., concerning issues of human health (organ or
organism) or environmental endpoints (organism or populations). The pathways connecting MIEs
and AOs are defined by key events (KEs) which represent measurable biological changes, and key
event relationships (KERs), i.e., the directed, predictive relationships among those KEs. AOPs are the
units of development for the AOP framework, and represent a single, nonbranching sequence of KEs,
linked by KERs, connecting a single MIE to a single AO [12].
Figure 1 gives an example of a generalized AOP and its components (Panel A), and shows how
AOPs can form interlinked networks based on overlapping MIEs, KEs and AOs (Panel B) that represent
the complex biology underlying disease processes [11]. Bioassays targeting the MIE and KEs in an AOP
were developed, characterized and used as endpoints as part of an IATA. The AOP framework defines
this entire conceptual approach that assembles and organizes mechanistic knowledge to communicate
causal links between biological perturbations and adverse health outcomes which are meaningful to
chemical risk assessments and regulatory decision making [2,13].
To help accelerate AOP development, strategies, principles and best practices have been established
to help scientists, regulators and decision makers understand and contribute to the AOP framework.
In 2014, Villeneuve et al. proposed a set of five core principles to guide AOP development [14]; these
are highlighted in Box 1.
Box 1. Core Tenets of AOPs [14].
1. AOPs are not chemical-specific. Specificity limits the predictive utility of AOPs for new substances.
2. AOPs are designed with modular units. These components should be reusable to enhance flexibility, and
they should be designed to accommodate differing levels of detail based on evidence.
3. AOPs are a unit of development. An individual AOP is defined as a single, nonbranching sequence of KEs,
linked by KERs, connecting a single MIE to a single AO. This structure reduces the complexity, and is a
practical unit for development and evaluation.
4. AOPs form networks. Multiple AOPs, sharing one or more common KE or KER, form networks that more
realistically represent the complexity of biological systems needed to make accurate biological predictions
of adverse toxicological outcomes.
5. AOPs should be continuously updated. New research should be used to inform and refine existing AOPs.
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Figure 1. (A) Generalized AOP showing the relationship between MIE, KEs and AOs, and the KERs
that connect them. Bioassays targeting the MIE and KEs in an AOP are characterized or developed as
part of an IATA. (B) AOPs can form interlinked networks based on overlapping MIEs, KEs and AOs
that better capture the complex biology of disease processes. (From [11]).
3.2. Current Status
Tremendous progress in AOP research and development has occurred since AOPs were first
described in 2010 [13]. A survey of papers published annually on the topic from 2010–2019 indicated
exponential growth, with almost 200 publications expected in 2020 based on a PubMed literature
search. This growth suggests that the AOP concept is gaining widespread traction and acceptance in
the academic community (Figure 2 [15]).Nanomaterials 2020, 10, x FOR PEER REVIEW 6 of 22 
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A number of efforts worldwide are contributing to AOP development; among these, the OECD is
spearheading one of the largest. The OECD AOP Development Programme was started in 2012, and is
overseen by the Extended Advisory Group on Molecular Screening and Toxicogenomics (EAGMST).
Its goal is to develop, review and officially endorse AOPs. AOP development is based on voluntary
contributions from member countries and stakeholders. It involves an internal review within EAGMST
to ensure compliance with AOP principles, as well as an external review by subject matter experts to
assess the scientific merit of the proposed pathway. There are currently nine OECD-endorsed AOPs,
seven that have received approved status, fourteen under review (indicating that they are at a late
stage of the endorsement process), and twenty-four proposals under active development.
The OECD, together with contributions from the U.S. EPA, the European Commission’s Joint
Research Centre and the U.S. Army Engineer Research and Development Center has also led the
development of the AOP Knowledge Base (AOP-KB). Launched in 2014, this web-based tool consists
of five modules to enable and promote the development and application of AOPs: the e.AOP.Portal,
the AOP-Wiki, the Effectopedia, the AOP Xplorer and the Intermediate Effects Database [12].
The AOP-Wiki serves as the primary repository for qualitative AOPs developed (including those
endorsed by the OECD) or under development. It is intended to foster collaboration among various
stakeholders contributing to AOP development following the standard OECD principles for developing
and assessing AOPs [16]. The AOP Wiki currently contains more than 200 AOPs, including more than
2000 defined KEs (Figure 3).Nanomaterials 2020, 10, x FOR PEER REVIEW 7 of 22 
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In addition to these efforts, various stakeholders have supported projects aimed at evaluating and
promoting the development of AOPs for MNs. The EU, through its H2020 initiative, has supported
several projects focused on the development and application of AOPs for MNs; these include
SmartNanoTox (Smart Tools for Gauging Nano Hazards) and PATROLS (Physiologically Anchored
Tools for Realistic nanOmateriaL hazard aSsessment) [9,14]. Since 2016, the OECD Working Party
on Manufactured Nanomaterials (WPMN) has included in its program the project Advancing Adverse
Outcome Pathway (AOP) Development for Nanomaterial Risk Assessment and Categorisation [NanoAOP
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Project; ENV/CHEM/NANO(2017)5]. These projects and their outcomes and contributions to AOP
development are discussed in Section 6.
4. Potential Applications of AOPs
Progress in AOP development has given rise to a range of potential applications. In chemical
risk assessment, the AOP framework is intended to guide and develop IATA. IATA is an approach
to characterizing the hazard of chemicals that integrates analyses of existing information with the
generation of new information through targeted testing strategies [12]. From a risk assessment
perspective, the AOP framework provides:
• A structured framework to evaluate existing information available for a chemical of interest;
potential sources include in chemico, in silico, in vitro, ex vivo, in vivo and ‘omics’ data;
• A way to identify data gaps and efficiently generate missing information to increase confidence in
decision making and assessments of risk;
• A framework to apply an iterative approach until sufficient information is gathered for
decision making.
Within this context, the AOP framework has several specific applications and benefits to improve
risk assessment and decision making for chemicals; these are summarized in Table 2 [12,15,17].
Of particular interest, the AOP concept offers a systematic, mechanistic framework to develop, assess,
use and interpret alternative testing strategies for chemical risk assessment and decision-making,
thereby reducing reliance on new substance testing. Applications in chemical safety assessment are
especially useful to regulatory toxicologists, risk assessors and risk managers, as well as to industry
stakeholders responsible for product stewardship and compliance with regulatory requirements [2].
Table 2. Potential applications and benefits of the AOP framework in chemical risk assessment.
1. Evaluation of existing information
• improve chemical grouping and categorization to fill data gaps by read-across
• utilize data developed from advances in alternative testing strategies, such as in chemico, in vitro, ex vivo
and ‘omic’ data, for decision making
• improve predictivity in safety assessment (e.g., quantitative structure–activity relationships)
2. Identification of data gaps and generation of new data
• improve high-throughput screening for chemical prioritization
• identify data gaps to inform relevant research
• identify novel biomarkers for hazard evaluation
• develop novel, nonanimal approaches for hazard characterization
• reduce reliance on animal testing
3. Iterative decision making
• increase confidence in nontraditional test methods
• use nontraditional data and methods to improve weight-of-evidence in decision making
One area of proposed application of AOPs is MN risk assessment and decision-making. Because
of their particulate aspects, MNs do not necessarily display classical dose-response relationships,
and their toxicity is not always predictable from chemical substance models. Moreover, the biological
effects of small changes in their physical and chemical makeup are not easily predicted with today’s
risk assessment toolbox and models. The benefits of a framework that is better suited to assessing the
impacts of such MN modifications can apply to regulators, researchers and product developers. One of
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the essential components of the mechanistic representation of MN-induced outcomes provided by
AOPs is the MIE, that triggers the pathway, and KEs, that can be directly steered by MN interactions
with biomolecules. The molecular level description of the initiating event and the underlying physical
interaction make it possible to relate the physicochemical properties of the MN to the probability of a
MIE via quantitative structure– or property–activity relationships (QSAR/QSPR). These relationships
help to identify the MN properties of concern, and thus, enable the consequent grouping of the MNs
based on their ability to induce a MIE/AOP. The main benefit of these relationships is the replacement
of biological testing with in silico or in vitro screening.
While not the focus of this discussion, the AOP framework has other potential applications that
extend beyond risk assessment [2]. AOPs provide utility in product discovery and development,
especially in the pharmaceutical and agrochemical industries; here, they can support preclinical safety
assessments to identify compounds, early in their development, which are potentially harmful to
human, animal or environmental health. In medicine and health, clinicians and researchers can
use AOP knowledge to understand disease pathways across multiple biological levels, informing
prevention, diagnosis and treatment efforts. Other stakeholders that may benefit from AOP applications
include academics (who may benefit from a unifying framework to increase the real-world impact of
their work) and nongovernmental organizations (NGOs), including animal welfare and environmental
NGOs. As mentioned, several focus areas in the proposed Horizon Europe Strategic Plan [18] could
benefit from advancements and the adoption of AOPs in decision making.
5. Recent Progress with AOPs for Nanosafety
Projects worldwide are focusing on meeting the challenges of AOP development and promoting
the use of AOPs for decision making. Below, projects contributing to the development, use and
adoption of AOPs for MNs are highlighted and summarized.
5.1. Progress in AOP Development for Manufactured Nanomaterials
Inhalation exposure to powdered MNs, especially during manufacture and handling, is a highly
relevant risk scenario [20]. Some studies have documented significant AOs such as fibrosis and cancer
following exposure to certain forms of MNs (e.g., carbon nanotubes [21]); however, considerable
uncertainty about the physical and chemical properties influencing these outcomes remains. In vivo
inhalation experiments to characterize the hazard of MNs are challenging and resource-intensive.
Of all standardized toxicity testing, inhalation studies are some of the most expensive to commission
and complete. To simulate realistic exposure, animals have to be exposed to low dose aerosols over
long periods of time (up to 2 years). Generating MN aerosols can be difficult (e.g., many are viscosity
modifiers), and often, alternative exposure methods such as pharyngeal aspiration or intratracheal
instillation must be used that deliver high bolus doses over short time frames [20]. The AOP framework,
as part of an IATA, offers a more time- and cost-efficient alternative approach to assessing the potential
risks from inhaled MNs; however, development and verification of the pathway is necessary before
such an approach can be used for decision making.
The SmartNanoTox project is using results from in vivo, in vitro and in silico research to develop
AOPs for adverse pulmonary effects following MN exposure. The effort is using representative sets of
MNs to identify critical KEs and KERs to construct AOPs and relate them to interactions at the bio-nano
interface [9]. Using the data generated from various KEs and KERs along the AOP, SmartNanoTox
aims to develop quantitative structure–activity relationships (QSARs) to enable predictions of whether
a MN can trigger an AOP and lead to an AO, and to enable the grouping, categorization and
read-across of MNs for these endpoints [22,23]. The PATROLS project has collated and generated
data to establish AOPs for both lung and liver inflammation, fibrosis and cancer AOs following
MN exposure. The purpose of this activity was, based on our understanding of AOPs, to identify
biomarkers which are suitable for long-term MN exposure effects that could be applied in short-term
in vitro assays to develop more targeted nonanimal hazard testing strategies with potentially higher
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predictive value. NanoCommons has implemented a tool for predicting occurrences of MIEs using
differentially expressed genes/proteins from high-throughput experiments to calculate a prioritized
list of MIEs with identified biological processes, while NanoSolveIT is developing the concept of
a nanomaterial fingerprint that captures the key physicochemical, biomolecular and interactional
features of a MN that are predictive of its toxicity.
Other related efforts are developing data, methods and tools which are useful for AOP
development [24–26]. For example, the EU’s NanoSolveIT project is developing: (i) innovative
modelling techniques and tools for nanoinformatics; (ii) an IATA to identify the specific characteristics
of MNs that are responsible for adverse effects on human health or the environment; and (iii) in silico
methods, models and tools which are useful for AOP development. The grouping strategies, data and
methods in the H2020 projects GRACIOUS and NanoReg 2 are being incorporated into IATA [27].
Similarly, NanoCommons aims to deliver a nanoinformatics research infrastructure including a database
to facilitate the reuse of existing nanosafety data, and in silico tools for analyses and predictions of MN
impacts, including tools to predict MIEs and AOPs. The Data and Knowledge on Nanomaterial (DaNa)
project has compiled data on the applications of MNs and the current state of knowledge. The EU
Cluster of Systems of Metadata for Official Statistics (COSMOS) is identifying common sets of metadata
objects with standard definitions and methods to build better metadata repositories. NanoCommons,
in collaboration with the National Cancer Institute working group on nanoinformatics, is supporting
the development of metadata standards for nanosafety research, as described in another paper in this
special issue [28]. All of these efforts can make significant contributions to AOP development.
5.2. Progress in the Application and Use of AOPs
One of the first AOPs officially endorsed by the OECD was the skin sensitization AOP (AOP No.
40 in the AOP-Wiki) [15]. Since its endorsement, mechanistic knowledge gained on skin sensitization
has been used to develop and validate three standardized in vitro tests targeting the KEs in the
AOP. These test guidelines have been published and are now accepted for regulatory use as a viable
alternative to traditional animal testing for skin sensitization. The skin sensitization AOP is a success
story, demonstrating how AOP development can help identify, promote development of, and validate
alternative testing strategies for chemical risk assessment without the use of animals.
While significant progress has been made in AOP development, application and use over the
last decade, for endpoints beyond skin sensitization, there is still a significant distance between the
current reliance on, reduction of, and replacement of animal testing with nonanimal approaches for
risk assessment and regulatory decision making. The OECD WPMN NanoAOP project is contributing
to both the development and application of AOPs for MN risk assessment. The goal of the project
was to develop a methodology to use existing nanotoxicology literature to support MN-relevant AOP
development. While not developing an AOP, a case study outlines how the literature can be mined to
identify and develop specific KEs to support AOP development.
As part of its outcomes, the OECD WPMN NanoAOP project convened two workshops to
gain expert feedback on the current status, use and future needs for AOPs which are relevant to
MNs in support of risk assessment. The consensus from experts is that currently, the primary
applications of AOPs are (i) to support hazard identification; (ii) grouping, categorization and
read-across; (iii) ranking and prioritizing MNs; (iv) the identification of novel biomarkers for alternative
test method development; (v) for product development as part of a safer manufacturing approach; and
(vi) together with ‘omics’ strategies, AOPs can be used to propose testing that could be predictive of
AOs. The ultimate goal is to use AOPs as the basis for regulatory decision making for MNs; however,
several challenges have been identified by experts that need to be overcome to advance the future use
of AOPs for MN risk assessment (discussed in Section 7). Experts suggest that to ensure the relevance
of AOP frameworks for regulatory decision making, development should proceed by first choosing an
AO relevant for regulators, and then developing the pathway working backwards toward an MIE.
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Several projects are contributing directly to the application and use of AOPs for MN risk
assessment. As described, SmartNanoTox and PATROLS are developing in vitro models, methods
and computational tools for MN hazard assessment targeting the KEs in developed AOPs. This is
an important step to ensure that identified KEs in an AOP can be assessed with validated methods
and tests, and thus, to support their inclusion in an IATA for MN risk assessment. SmartNanoTox
is constructing simplified in vitro or in silico tests for the AOPs developed in their project, targeting
identified MIEs and KEs for adverse respiratory outcomes from MN inhalation. PATROLS is focused
on developing mechanism-based, nonanimal methods, models and computational tools for MN
hazard characterization, targeting the KEs in established AOPs. This includes in silico hazard testing
systems, in vitro human tissue models, ecotoxicology models and methods for MN characterization in
biological systems.
6. Challenges in the Development and Application of AOPs
Substantial progress has been made toward the development and application of AOPs, but a
number of challenges remain before their full potential can be realized. A global horizon scanning
exercise to identify current challenges toward the regulatory adoption of the AOP framework is one of
the largest efforts to advance AOP development and application [29]. The key findings from that effort
are summarized below, as are expert insights from the workshops held as part of the OECD NanoAOP
project. Limitations identified through these efforts include challenges specific to MNs, as well as
outstanding research and technical needs hindering AOP development more generally.
6.1. Nanomaterial-Specific Challenges
The development and application of AOPs for MN decision making pose a specific set of challenges,
summarized as follows:
6.1.1. Limitations of Current Literature
Although there have been significant advancements in nanosafety and nanotoxicology research
over the last two decades [30], there are several limitations of the literature for AOP development
and use. Limitations include (i) a lack of complete understanding of the biological mechanisms of
action underlying MN-induced adverse health effects; (ii) uncertainty from the different exposure
conditions and models (e.g., assays, cell lines, etc.) used in each study; (iii) limited consideration
of MN dispersion and dosimetry; (iv) a general lack of physical and chemical characterizations of
MNs (see Influence of Physical and Chemical Properties, below); and (v) fragmentation of the data [31–33].
Better data creation and management processes for MNs are required to advance the development and
use of the AOP framework, and future data reporting needs to include a set of minimum information
requirements [31], although, as noted in Box 2, there are efforts underway to address this challenge.
6.1.2. Assays and Methods to Assess MIEs and KEs
To use AOPs for decision making about MNs, there is a need to identify which KEs are critical for
testing as part of an IATA. To apply AOPs to chemical risk assessments, strategies to evaluate specific
MIEs and KEs must be developed and verified [7]. Many of these assays and testing strategies exist
for conventional chemicals, but toxicity testing of MNs often requires modification [34–37]. Method
development, including verification of MN-appropriate methods, is needed, and remains an on-going
challenge, although significant progress in being made. Highlighted needs specific to MNs arising
from expert discussions include the incorporation of accurate dosimetry into toxicity testing, which
includes consideration of the most relevant dose metrics (e.g., mass, surface area, or particle number)
and exposure conditions (e.g., stability of suspensions and characterization of agglomerates) [38].
In developing assays and methods to assess MIEs and KEs, reproducibility and accessibility to testing
methods need to be considered. Further, assays and methods will have to be evaluated for their
relevance to a given AOP; some assays may be relevant to more than one AO. Multiple assays may be
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required to evaluate KEs and ensure specificity to a given AOP (e.g., assays looking at cytotoxicity via
different mechanisms, such as apoptosis versus necrosis). A key gap for both chemicals and MNs is the
development of AOPs for ecotoxicity, a topic that is being addressed in RiskGONE and NanoSolveIT.
Box 2. Projects contributing to the development, use and adoption of AOPs for MNs.
SmartNanoTox
Conducting in vivo, in vitro and in silico research to
develop AOPs for adverse pulmonary effects following
MN exposure. Research is being used to develop
simplified in vitro or in silico tests for the AOPs
developed in the project, targeting identified MIEs and
KEs for adverse respiratory outcomes from MN
inhalation.
PATROLS
Developing mechanism-based, nonanimal methods,
models and computational tools for MN hazard
characterization, targeting the KEs in established AOPs.
This includes in silico hazard testing systems, in vitro
human tissue models, ecotoxicology models and
methods for MN characterization in biological systems.
OECD WPMN NanoAOP
Developed a methodology and approach to use existing
nanotoxicology literature to support MN-relevant AOP
development and its use in decision making.
NanoSolveIT
Developing: (i) innovative modeling techniques and
tools for nanoinformatics; (ii) an IATA to identify the
specific characteristics of MNs that are responsible for
adverse effects on human health or the environment;
and (iii) in silico methods, models and tools which are
useful for AOP development using toxicogenomics
data and linked to nanomaterial “fingerprints”. See
also [19].
NanoCommons
Developing a nanoinformatics research infrastructure
including a knowledge base to facilitate the reuse of
existing nanosafety data, tools to support Open and
FAIR data curation and annotation, and in silico tools
for analysis and prediction of MN environmental and
human health impacts.
GRACIOUS
Developing a grouping strategy for MNs that can be
incorporated into an IATA.
COSMOS
Identifying common sets of metadata objects with
standard definitions and methods to build better
metadata repositories.
DaNa
A database with important and generally
understandable information on health and the
environment as they relate to the application of
nanomaterials, as well as data on the safety of
manufactured nanomaterials.
RiskGONE
Developing science-based risk governance of MNs
based on an understanding of risks and risk
management practices. The project is developing new
tools and/or modifying existing ones to identify the
environmental and human health impacts of MNs.
AOPs for human and environmental end-points are
being developed. These tools will be integrated into the
work of a European Risk Governance Council to
provide governance decisions on the safety of the
specific materials.
NanoReg2
Aimed to couple ‘safe-by-design’ (SbD) to the
regulatory process, using value chain implementation
studies to establish SbD as a fundamental pillar in the
validation of a novel NMs. Grouping concepts
developed by NanoReg2 were prepared as guidance
documents to support industries or regulatory agencies.
6.1.3. Influence of MN Physical and Chemical Properties
Traditional chemical properties such as solubility, hydrophobicity and chemical composition are
known to influence the toxicity of MNs. However, MN toxicity can also be influenced by distinct
physical–chemical properties, such as dissolution rate (ion release), electronic band gap, aspect ratio,
dispersibility in solution, large surface area to volume ratios or increased surface reactivity [39].
AOPs are generally developed with data from conventional, bulk chemicals; their application to
MN risk assessment requires evaluation to ensure that MN-relevant mechanisms, MIEs and KEs are
captured [9,11]. In particular, workshop experts identified that one issue facing MN-relevant AOP
development is the lack of identified MIEs. For MNs, MIEs may be physical rather than molecular
in nature (e.g., frustrated phagocytosis); research and AOP development will need to account for
these particle-specific mechanisms. Currently, there are nine OECD-endorsed AOPs, seven that have
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received approved status, fourteen under review, and twenty-four proposals under active development,
which could be assessed for their relevance to MNs.
Despite these challenges, workshop experts concluded that the AOP framework would improve
risk assessment strategies for MNs, and further the community’s understanding of toxicity mechanisms
and potency. Realizing this potential requires addressing outstanding technical challenges and
barriers to adoption, i.e., both those specific to MNs (described above) and those that apply to AOPs
more generally.
6.2. Technical Challenges
6.2.1. AOP Networks
Individual AOPs are constructed as linear sequences of biological events connecting a MIE to
an AO. However, exposure to chemicals, including MNs and other emerging substances, may affect
more than one MIE or KE, and result in one or many AOs. Individual AOP units are intended to form
networks of interconnected KEs to reflect this complexity, but little guidance is currently available to
develop, analyze and evaluate these networks [9].
6.2.2. Exposure and Dose
Risk assessment requires information on the exposure conditions (e.g., route, dose, duration and
frequency) needed to cause an AO. Quantitative AOPs (qAOPs), which use quantitative data to predict
risk of an AO under specific exposure conditions, are proposed as a solution to address these needs,
but few examples currently exist.
6.2.3. Individual and Interspecies Differences
Additional challenges include how to develop AOPs that can account for individual variation,
such as life stage, immune status or sex, and how to reduce the uncertainty that arises from interspecies
differences, including sensitivity, potency and metabolic diversity.
6.2.4. Repair Mechanisms
Many key biological events, although triggered with exposure, can resolve over time and do
not result in an AO. Such repair mechanisms may not be accounted for in the AOP framework,
and identifying ‘points of no return’ toward an AO is important for using the AOP framework for
decision making. Consideration of dose-response (i.e., exposure) within the framework would help
account for repair mechanisms.
6.3. Barriers to Adoption
6.3.1. Lack of Guidance for Risk Assessors
Guidance is needed for risk assessors outlining the use and application of AOPs for
decision-making. Such guidance should help risk assessors determine whether the level of development
for an AOP and weight of evidence provided when using it as part of an IATA are adequate for
decision-making. The emerging consensus is that the level of understanding and degree of confidence
needed will depend on the intended application and severity of the AO, i.e., whether an AOP is
‘fit-for-purpose’ must be evaluated on a case-by-case basis. For example, for AOPs with more severe
outcomes (e.g., fibrosis or cancer), an IATA would likely require a battery of validated tests spanning
several KEs in the pathway to establish the weight-of-evidence needed for decision-making. Further,
negative results would require a higher burden of proof. Establishing guidance on this topic would
help accelerate AOP adoption.
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6.3.2. Engagement of Multiple Stakeholders
The development of AOPs requires a significant investment of resources, time and expertise.
Engagement of multiple stakeholders with a broad range of expertise is essential; coordination and
cooperation are needed for efficient, high-quality AOP development. Multistakeholder participation
is critical to increase confidence in the framework and to support its transition toward use in
policy, decision making and regulatory applications, but challenges exist in engaging participants.
These include, among others, a lack of adequate incentives, problems with information control and
ownership, reputational and liability risks associated with developing AOPs for decision making
purposes, resource demands and limitations, cross-discipline communication challenges and the need
for oversight [2].
6.3.3. Communication
Even among experts, misconceptions about the AOP framework exist. In the horizon scanning
effort, community collaboration and communication were identified as critical components of AOP
development and acceptance.
7. Summary
The adoption of AOPs for advanced materials and MNs is hindered by the lack of accepted
methods for toxicity evaluation and over-reliance on resource-intensive animal testing. There is a need
and an opportunity to develop smarter approaches for screening and prioritizing novel nanoscale
materials for decision-making. The AOP framework is a promising and toxicologically realistic
approach to help address several current challenges of chemical and nano-specific safety assessments.
Significant progress has been made in AOP development, application and use over the last decade
including methods, tools and assessment approaches. However, we are still a long way from reliance
on—and the replacement of animal testing with—nonanimal approaches. Several challenges remain
and must be addressed to realize the full potential of AOPs. Projects worldwide are focusing on meeting
these challenges and advancing the use of AOPs for decision-making. International cross-disciplinary
analyses and deliberation will improve the adoption and acceptance of the AOP framework, including
for MNs.
8. The Way Forward
To advance the development, use and acceptance of the AOP framework for risk assessment and
decision making, and to help overcome the challenges identified above, several actions are suggested
which aim at promoting nine central recommendations (Table 3). The ‘central recommendations’
(Table 3) are meant to be high-level goals, with the ‘actions’ the means of achieving them, broken out
by timing. Although these recommendations and corresponding actions are tailored to promoting the
development, use and acceptance of AOPs, they share overlapping goals with the nanosafety research
community at large. Actions addressing these central recommendations are organized by timelines
expected for completion: short-, medium- and long-term.
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Table 3. Central Recommendations for Promoting the Development, Use and Acceptance of the AOP Framework for MN Decision Making.
1. Advance MN-relevant and Advanced Material Considerations in AOP Development
The AOP framework requires the continued development of predictive pathways, building on the efforts of the toxicology community via the AOP Wiki. Needs include updates to
toxicological mechanisms within AOPs that identify processes and considerations relevant to MN toxicity. Further, the path for emerging advanced and hybrid materials to use the AOP
Framework for early-stage safety decisions can be outlined from these efforts. Recommendations include:
Short-term Actions Medium-term Actions Long-term Actions
1. Establish the types of data required to develop AOPs for MNs
and identify existing NM-relevant AOPs;
2. Compare molecular initiating events (MIEs), key events (KEs),
key event relationships (KERs) and adverse outcomes (AOs)
identified for MNs to AOPs in the AOP Wiki;
3. Identify MN-relevant MIEs, KEs and KERs. Research should
include identifying MN-relevant mechanisms and MIEs, which
are often based upon physical interactions with MNs instead of
molecular ones (e.g., frustrated phagocytosis and
particle-surface-induced reactive oxygen species [9]).
1. Identify similarities and differences in MIEs, KEs and KERs
between other emerging advanced materials and MNs [9];
2. Conduct targeted research on MNs to elucidate the effect of
interspecies variability on AOPs and the development of
related testing strategies [40,41]. This can include
side-by-side testing of in vitro cell lines and 3D models from
a number of species exposed to a suite of MNs to examine
conserved mechanisms and potencies;
3. Use ‘omics’ approaches to identify gene, protein and
metabolite markers of MN exposure (e.g., using heatmaps)
and their implications for AOP development [24,39,42].
1. Develop data sets for quantitative AOPs (qAOPs)
that include consideration of the exposure conditions
necessary for MN risk assessment. This includes
adopting formal definitions and structures for qAOPs
and developing case studies outlining the development
and use of qAOPs for MNs;
2. Develop a testing strategy for advanced and hybrid
materials (smart and responsive materials) to identify
and quantify MIEs, KEs, KERs and AOs [9];
3. Convene experts to discuss how AOPs can account
for individual (e.g., sex or life-stage) and interspecies
variations which can be then used to reduce the
associated uncertainty for decision making.
2. Utilize Existing Data from the Literature and Previous Projects
A diverse set of data has been developed that may be useful for furthering the development, application and use of AOPs for MN risk assessment. So far as possible, these data should be
taken advantage of to advance knowledge and identify opportunities for additional AOP development. This requires extensive expert-driven curation efforts. Recommendations include:
Short-term Actions Medium-term Actions Long-term Actions
1. Evaluate data quality from the peer review literature and
current suite of in vitro assays based on identified KEs;
2. Encourage researchers (and publishers) to make their raw
toxicology data from peer-reviewed literature available publicly;
3. Harmonize formats for reporting toxicology data (including
negative results) to facilitate the development of databases;
4. Build searchable databases for priority MNs that includes
funded research and literature (e.g., available data developed
under NanoCommons, eNanoMapper, NanoReg2, GRACIOUS
and DaNa projects), as well as traditional chemical databases
(e.g., TOXCAST). Efforts should include collecting negative data.
1. Develop guidance on how the existing nanotoxicity
literature, despite its documented limitations (e.g., minimal
reporting of physical and chemical characteristics), can be
used for AOP development and decision making;
2. Broaden access and use of existing data sources (e.g.,
Nanomaterial-Biological Interactions Knowledgebase,
Nanomaterials Knowledge Informatics Commons (NIKC);
eNanoMapper, NanoCommons KnowledgeBase) and other
resources;
3. Evaluate publicly available REACH data for MNs in terms
of use in AO and predictive modeling;
4. Identify novel biomarkers for hazard evaluation;
5. Develop research projects to fill data gaps for identified
endpoints.
Create processes to continually update publicly
available databases as new data is developed.
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3. Promote Reliable and Quantitative MN Data Generation and Management
High quality data are essential to ensure that MN-relevant AOPs can be developed and used in decision making. Guidance is needed on the types of data and reporting
standards to enable the use of AOP in regulatory decision making. Coordinated efforts among stakeholders will improve efficiency and limit additional testing.
Recommendations include:
Short-term Actions Medium-term Actions Long-term Actions
1. Identify priority AOs observed with MNs and initiate
research into AOP development for these AOs;
2. Standardize the endpoints and reporting elements of
assays evaluating MIEs, KEs and KERs so that high
quality, comparable data is generated, published and
added to databases, including negative data;
3. Develop guidance on the types of data that need to be
generated and reported by the research community for
their work to be useful in regulatory decision making.
1. Generate data to allow for grouping – data
collection/mining to determine the mode of action using
MNs that can represent groups of
MNs/functionalizations;
2. Develop MN-specific resources (for the AOP Wiki) to
encourage the coordination and cooperation among
stakeholders which is needed for efficient, high-quality
AOP development.
1. Advance modeling and QSAR databases and link to
the physical and chemical attributes of MNs;
2. Adopt iterative decision making, including increased
confidence in nontraditional methods and use of
nontraditional data and methods to improve
weight-of-evidence in decision making.
4. Advance Knowledge of the Quantitative Relationships Between MN Physical and Chemical Characteristics and AOP Elements
A better understanding of the quantitative relationships between MN physical and chemical characteristics and toxicological outcomes is required. It is recommended to:
Short-term Actions Medium-term Actions Long-term Actions
1. Review findings of existing data and research on the
relationships between physical and chemical properties
and MN KEs, including MIEs, AOs and KERs;
2. Develop hypotheses of predictive relationships
between MN physical and chemical properties and
biological outcomes.
1. Test predictive physical and chemical relationships of
MNs to biological outcomes, using carefully controlled
changes within and across materials (furthering the
work of the projects which inaugurated this effort, such
as SmartNanoTox and NanoMILE);
2. Assess the importance of using alternative dose
metrics to mass (e.g., surface area, particle number) in
predicting toxicological outcomes for MNs;
3. Where appropriate, incorporate alternative dose
metrics into developed benchmark levels for MNs for
screening and risk assessment.
1. Develop quantitative structure–activity relationships
(QSAR) as predictive tools for KEs.
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5. Identify Current Applications of the AOP Framework for MN Decision Making
Current applications of the AOP framework (e.g., prioritization, grouping and read-across) can be adopted into decision making. It is recommended to:
Short-term Actions Medium-term Actions Long-term Actions
1. Identify screening-level MN safety decisions that are
fit-for-purpose/can rely on AOPs;
2. Incorporate AOP elements into grouping and
read-across decision trees for MNs.
1. Adopt a testing scheme/decision tree for MN
grouping and read-across;
2. Develop guidance and case studies for use of AOPs
in regulatory decision making (e.g., MN prioritization;
grouping, categorization and read-across; and hazard
identification and ranking).
1. Develop guidance and case studies for the use of
AOPs in product development decision making, and
the implementation of a safe-by-design approach.
6. Establish Test Methods and Protocols which are Useful for MN Decision Making
Test methods to accurately measure MN-relevant MIEs and KEs are required to advance the use of AOPs as part of an IATA for MN decision making. The development (and
verification) of harmonized and standardized MN-relevant test methods is needed:
Short-term Actions Medium-term Actions Long-term Actions
1. Evaluate, advance or develop physical and chemical
characterization protocols for MNs and determine how
they can be used to identify MIE, KE and AO portions
of the AOP framework;
2. Prioritize KEs and the assays/methods to characterize
them for development, with KEs closer to an AO being
prioritized to ensure relevance for regulatory decision
making as part of an IATA;
3. Evaluate, advance or develop in silico, in chemico,
in vitro and ex vivo assays for MNs and determine how
they can be used to characterize MIE, KE and AO
portions of the AOP framework [24];
4. Initiate Test Guideline development for assays
tailored to MNs that address considerations such as
physical and chemical characterization, dispersion and
dosing relevant to AOPs;
5. Develop guidance on the minimum level of
validation required for a given in vitro assay or method
for regulatory decision making.
1. Create voluntary standard methods for IATA;
2. Consider the formal adoption of IATA for certain MN
hazard or risk decisions;
3. Advance new in vitro test development to screen for
MIEs and KEs;
4. Identify test methods (including in silico) for high
throughput screening.
1. Develop OECD test guidelines for MNs that relate to
MIEs, KEs and AOs;
2. Where appropriate, formally adopt IATA for MNs;
3. Adopt harmonized, standardized tests for high
throughput screening.
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7. Demonstrate Predictive Capability of AOPs and In Vitro Test Methods
A coordinated effort is needed to ensure alternative testing strategies are predictive of adverse outcomes of regulatory relevance. Recommendations include:
Short-term Actions Medium-term Actions Long-term Actions
1. Assess the strength of evidence for considering
dose-response relationships in AOPs as predictive tools
for MN risk assessment.
1. Compare the predictive capability of in vitro assays
for MIEs and KEs with in vivo observations or
epidemiological data;
2. Design and conduct side-by-side in vitro and in vivo
testing for representative MNs to compare toxicity
mechanisms and potency across MNs and assays
(furthering the work of the projects that inaugurated
this effort, such as PATROLS).
1. Develop and test predictive alternative testing
models;
2. Validate predictive alternative testing models.
8. Guidance to Facilitate Adoption of MN-relevant AOPs for MN Decision Making
The science required to address the technical challenges of transitioning to alternative (i.e., nonanimal) toxicity testing is progressing, but efforts are needed to translate and
incorporate these developments into decision making about the safety of MNs. Recommendations include:
Short-term Actions Medium-term Actions Long-term Actions
1. Identify MN-relevant and MN-specific AOPs, KEs
and KERs, including assessments of the AOPs which
have been officially OECD-endorsed, approved or are
under review and under active development for
MN-relevance (e.g., https://aopwiki.org/aops/173)
1. Develop and validate an IATA based on KEs, KERs
and AOPs that can be used in risk assessments of new
nanoscale materials. This includes identifying and
prioritizing which KEs are critical for testing as part of
an IATA, building on the work currently ongoing in
NanoSolveIT;
2. Develop guidance for risk assessors on developing an
IATA based on AOP frameworks for MN safety
assessments. This should include how to pick critical
KEs, or a suite of KEs, for testing.
1. Incorporate technical developments into specific
regulatory guidance/policy documents.
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9. Stakeholder Communication and Engagement on the Use of AOPs for MN Decision Making
To facilitate the development, adoption and use of the AOP framework for MN decision making, the engagement of multiple stakeholders with a broad range of expertise is
essential, and coordination and cooperation are needed. Recommendations include:
Short-term Actions Medium-term Actions Long-term Actions
1. Develop communication and educational materials
on the use of the AOP framework for MN decision
making for nontechnical stakeholders;
2. Organize additional workshops which seek to
encourage participation from various stakeholders with
a vested interest in AOP development and application
for MN decision making, including academics,
policy-makers, regulators and industry.
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